Abstract
Abundant expression of somatostatin receptors (SSTR) is frequently identified in differentiated neuroendocrine tumors and may serve as potential target for diagnostic imaging and treatment. This article discusses the "theranostic approach" of SSTR-targeting compounds including an overview of its role for diagnosis, staging and restaging, discussing its way to being established in clinical routine, and giving an outlook about further potentially relevant developments.
MeSH terms
-
Gallium Radioisotopes / therapeutic use
-
Humans
-
Lutetium / therapeutic use
-
Neuroendocrine Tumors / diagnostic imaging*
-
Neuroendocrine Tumors / metabolism
-
Neuroendocrine Tumors / radiotherapy*
-
Radioisotopes / therapeutic use
-
Radionuclide Imaging
-
Radiopharmaceuticals / therapeutic use*
-
Receptors, Somatostatin / metabolism
-
Yttrium Radioisotopes / therapeutic use
Substances
-
Gallium Radioisotopes
-
Radioisotopes
-
Radiopharmaceuticals
-
Receptors, Somatostatin
-
Yttrium Radioisotopes
-
Lutetium